MiR-155 Promotes Uveal Melanoma Cell Proliferation and Invasion by Regulating NDFIP1 Expression

Overview

Journal Technol Cancer Res Treat

Specialties Biomedical Engineering
Oncology
Pharmacology

Date 2018 Jan 16

PMID 29333944

Citations 30

Authors

Jing Peng

Honglei Liu

Cuihong Liu

Affiliations

Soon will be listed here.

Abstract

MicroRNAs refer to small RNA molecules that destroy the messenger RNA by binding on them inhibiting the production of protein. However, the role of miR-155 in uveal melanoma metastasis remains largely unknown. In this study, we found that miR-155 was upregulated in both uveal melanoma cells and tissues. Transfection of miR-155 mimic into uveal melanoma cells led to an increase in cell growth and invasion; in contrast, inhibition of miR-155 resulted in opposite effects. Also, we identified Nedd4-family interacting protein 1 as a direct target of miR-155, and the expression of Nedd4-family interacting protein 1 was inhibited by miR-155. Furthermore, ectopic expression of Nedd4-family interacting protein 1 restored the effects of miR-155 on cell proliferation and invasion of uveal melanoma cells. In conclusion, miR-155 acts as a tumor promotor in uveal melanoma through increasing cell proliferation and invasion. Thus, miR-155 might serve as a potential therapeutic target in patients with uveal melanoma.

Citing Articles

Screening the human miRNA interactome reveals coordinated up-regulation in melanoma, adding bidirectional regulation to miRNA networks.

Jame-Chenarboo F, Reyes J, Twells N, Ng H, Macdonald D, Hernando E Sci Adv. 2025; 11(2):eadr0277.

PMID: 39792681 PMC: 11721578. DOI: 10.1126/sciadv.adr0277.

Exploring of miR-155-5p, miR-181b-5p, and miR-454-3p Expressions in Circulating Cell-Free RNA: Insights from Peripheral Blood of Uveal Malignant Melanoma Patients.

Masoumeh H, Tunay D, Demet O, Samuray T, Hulya Y Biochem Genet. 2024; .

PMID: 38914847 DOI: 10.1007/s10528-024-10849-8.

Genetic and Epigenetic Features of Uveal Melanoma-An Overview and Clinical Implications.

Pasalic D, Nikuseva-Martic T, Sekovanic A, Kastelan S Int J Mol Sci. 2023; 24(16).

PMID: 37628989 PMC: 10454135. DOI: 10.3390/ijms241612807.

MicroRNA-155 and Disease-Related Immunohistochemical Parameters in Cutaneous Melanoma.

Fawzy M, Ibrahiem A, Bayomy N, Makhdoom A, Alanazi K, Alanazi A Diagnostics (Basel). 2023; 13(6).

PMID: 36980512 PMC: 10047208. DOI: 10.3390/diagnostics13061205.

NDFIP1 limits cellular TAZ accumulation via exosomal sorting to inhibit NSCLC proliferation.

Cheng Y, Lu X, Li F, Chen Z, Zhang Y, Han Q Protein Cell. 2023; 14(2):123-136.

PMID: 36929005 PMC: 10019574. DOI: 10.1093/procel/pwac017.

References

Georgescu M . PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer. 2011; 1(12):1170-7. PMC: 3092286. DOI: 10.1177/1947601911407325. View

Behbahani G, Mohammadi Ghahhari N, Javidi M, Molan A, Feizi N, Babashah S . MicroRNA-Mediated Post-Transcriptional Regulation of Epithelial to Mesenchymal Transition in Cancer. Pathol Oncol Res. 2016; 23(1):1-12. DOI: 10.1007/s12253-016-0101-6. View

Howitt J, Lackovic J, Low L, Naguib A, Macintyre A, Goh C . Ndfip1 regulates nuclear Pten import in vivo to promote neuronal survival following cerebral ischemia. J Cell Biol. 2012; 196(1):29-36. PMC: 3255971. DOI: 10.1083/jcb.201105009. View

Kinoshita T, Yip K, Spence T, Liu F . MicroRNAs in extracellular vesicles: potential cancer biomarkers. J Hum Genet. 2016; 62(1):67-74. DOI: 10.1038/jhg.2016.87. View

Ji J, Xu M, Tu J, Zhao Z, Gao J, Chen M . MiR-155 and its functional variant rs767649 contribute to the susceptibility and survival of hepatocellular carcinoma. Oncotarget. 2016; 7(37):60303-60309. PMC: 5312385. DOI: 10.18632/oncotarget.11206. View

Oliva M, Rullan A, Piulats J . Uveal melanoma as a target for immune-therapy. Ann Transl Med. 2016; 4(9):172. PMC: 4876283. DOI: 10.21037/atm.2016.05.04. View

Momtazi A, Shahabipour F, Khatibi S, Johnston T, Pirro M, Sahebkar A . Curcumin as a MicroRNA Regulator in Cancer: A Review. Rev Physiol Biochem Pharmacol. 2016; 171:1-38. DOI: 10.1007/112_2016_3. View

Su Z, Yang Z, Xu Y, Chen Y, Yu Q . MicroRNAs in apoptosis, autophagy and necroptosis. Oncotarget. 2015; 6(11):8474-90. PMC: 4496162. DOI: 10.18632/oncotarget.3523. View

Tarlan B, Kiratli H . Uveal Melanoma: Current Trends in Diagnosis and Management. Turk J Ophthalmol. 2016; 46(3):123-137. PMC: 5076295. DOI: 10.4274/tjo.37431. View

10.

Field M, Durante M, Decatur C, Tarlan B, Oelschlager K, Stone J . Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas. Oncotarget. 2016; 7(37):59209-59219. PMC: 5312306. DOI: 10.18632/oncotarget.10962. View

11.

Abdel-Rahman M, Yang Y, Zhou X, Craig E, Davidorf F, Eng C . High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. J Clin Oncol. 2005; 24(2):288-95. DOI: 10.1200/JCO.2005.02.2418. View

12.

Sharma S, Kelly T, Jones P . Epigenetics in cancer. Carcinogenesis. 2009; 31(1):27-36. PMC: 2802667. DOI: 10.1093/carcin/bgp220. View

13.

Okumura N, Yoshida H, Kitagishi Y, Nishimura Y, Matsuda S . Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer. Biochem Biophys Res Commun. 2011; 413(3):395-9. DOI: 10.1016/j.bbrc.2011.08.098. View

14.

Iorio M, Croce C . MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009; 27(34):5848-56. PMC: 2793003. DOI: 10.1200/JCO.2009.24.0317. View

15.

Howitt J, Low L, Putz U, Doan A, Lackovic J, Goh C . Ndfip1 represses cell proliferation by controlling Pten localization and signaling specificity. J Mol Cell Biol. 2015; 7(2):119-31. DOI: 10.1093/jmcb/mjv020. View

16.

Caltabiano R, Puzzo L, Barresi V, Ieni A, Loreto C, Musumeci G . ADAM 10 expression in primary uveal melanoma as prognostic factor for risk of metastasis. Pathol Res Pract. 2016; 212(11):980-987. DOI: 10.1016/j.prp.2016.08.003. View

17.

Leal J, LLeonart M . MicroRNAs and cancer stem cells: therapeutic approaches and future perspectives. Cancer Lett. 2012; 338(1):174-83. DOI: 10.1016/j.canlet.2012.04.020. View

18.

Liu W, Zhao Y, Zhang T, Zhou L, Cui Q, Zhou W . MLH1 as a direct target of MiR-155 and a potential predictor of favorable prognosis in pancreatic cancer. J Gastrointest Surg. 2013; 17(8):1399-405. DOI: 10.1007/s11605-013-2230-5. View

19.

Kopp K, Ralfkiaer U, Gjerdrum L, Helvad R, Pedersen I, Litman T . STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle. 2013; 12(12):1939-47. PMC: 3735708. DOI: 10.4161/cc.24987. View

20.

Stahlhut C, Slack F . MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications. Genome Med. 2013; 5(12):111. PMC: 3978829. DOI: 10.1186/gm516. View